H11: section a through f - the information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.The following were reviewed as part of this investigation: patient severity, trend analysis, applicable previous investigation(s), sample (if available), and applicable fmea documents.Based on a review of this information, the following was concluded: the complaint of safety mechanism failure to activate was confirmed; however, the root cause was not identified.The product returned for evaluation was one 22ga x 0.75¿ safestep safety infusion set with y-site.Usage residues were observed throughout the sample.The safety mechanism was not engaged.White residue was observed within the safety plate.Initial attempts to activate the safety mechanism were unsuccessful.The springs were immobile due to the adhered residue.Microscopic inspection of the sample confirmed the presence of residue within the safety mechanism which appeared to immobilize the springs.Spring mobility and successful safety activation was established through gentle manipulation.The residue observed within the safety mechanism initially prevented proper safety function; however, the source of the residue was not identified.Consequently this complaint is confirmed as ¿cause unknown¿ at this time.H3 other text : evaluation findings are in section h.11.
|